tirzepatide off label use B.C. limits sale of 2 more diabetes drugs used for weight loss What Is “Off-Label Use,” and
Description
Black Friday Starts NOW
GLP-1 medication for chronic weight management
Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.
In prespecified secondary analyses, treatment groups were analyzed for an expanded list of CV, CKD, PAD, and HF outcomes
